Comparison of Dopamine and Norepinephrine in the Treatment of Shock
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Both dopamine and norepinephrine are recommended as first-line vasopressor agents in the treatment of shock. There is a continuing controversy about whether one agent is superior to the other. METHODS: In this multicenter, randomized trial, we assigned patients with shock to receive either dopamine or norepinephrine as first-line vasopressor therapy to restore and maintain blood pressure. When blood pressure could not be maintained with a dose of 20 microg per kilogram of body weight per minute for dopamine or a dose of 0.19 microg per kilogram per minute for norepinephrine, open-label norepinephrine, epinephrine, or vasopressin could be added. The primary outcome was the rate of death at 28 days after randomization; secondary end points included the number of days without need for organ support and the occurrence of adverse events. RESULTS: The trial included 1679 patients, of whom 858 were assigned to dopamine and 821 to norepinephrine. The baseline characteristics of the groups were similar. There was no significant between-group difference in the rate of death at 28 days (52.5% in the dopamine group and 48.5% in the norepinephrine group; odds ratio with dopamine, 1.17; 95% confidence interval, 0.97 to 1.42; P=0.10). However, there were more arrhythmic events among the patients treated with dopamine than among those treated with norepinephrine (207 events [24.1%] vs. 102 events [12.4%], P<0.001). A subgroup analysis showed that dopamine, as compared with norepinephrine, was associated with an increased rate of death at 28 days among the 280 patients with cardiogenic shock but not among the 1044 patients with septic shock or the 263 with hypovolemic shock (P=0.03 for cardiogenic shock, P=0.19 for septic shock, and P=0.84 for hypovolemic shock, in Kaplan-Meier analyses). CONCLUSIONS: Although there was no significant difference in the rate of death between patients with shock who were treated with dopamine as the first-line vasopressor agent and those who were treated with norepinephrine, the use of dopamine was associated with a greater number of adverse events. (ClinicalTrials.gov number, NCT00314704.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dopamine (DA) is a neurotransmitter in the catechol family, which is often used as first-line vasoactive drug in patients with septic shock (43).”
From Dopamine Is a Siderophore-Like Iron Chelator That Promotes Salmonella enterica Serovar Typhimurium Virulence in Mice (2019) · cites this paper as [43]
Citations
Cites
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Vincent, J. L., Moreno, R., Takala, J., Willatts, S., De Mendonça, A., Bruining, H., Reinhart, C. K., Suter, P. M., & Thijs, L. G. (1996) · Intensive Care Medicine · doi:10.1007/bf01709751 · Cited by 11,674
Self-citationWriting Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationCDC definitions for nosocomial infections, 1988
Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., & Hughes, J. M. (1988) · American Journal of Infection Control · doi:10.1016/0196-6553(88)90053-3 · Cited by 5,672
CDC definitions for nosocomial infections
Yangco, B. G. (1989) · American Journal of Infection Control · doi:10.1016/s0196-6553(89)80013-6 · Cited by 3,770
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Treating Patients with Severe Sepsis
Wheeler, A. P., & Bernard, G. R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901213400307 · Cited by 992
Current Epidemiology of Septic Shock: The CUB-Réa Network
Annane, D., Aegerter, P., Jars-Guincestre, M. C., & Guidet, B. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2201087 · Cited by 637
Research works printed but not linked: 1
- Mullner M, 2004, Cochrane Database Syst Rev, 3, CD003709
Cited by
Items 101–200 of 1,000
Effects of changes in arterial pressure on organ perfusion during septic shock
Thooft, A., Favory, R., Salgado, D. R., Taccone, F. S., Donadello, K., De Backer, D., Creteur, J., & Vincent, J.-L. (2011) · Critical Care · doi:10.1186/cc10462 · Cited by 226
“Its strong alpha-adrenergic properties make it a very effective vasopressor agent [22], and it is now considered the vasopressor of choice [23].”
BackgroundSelf-citationMcIntyre, W. F., Um, K. J., Alhazzani, W., Lengyel, A. P., Hajjar, L., Gordon, A. C., Lamontagne, F., Healey, J. S., Whitlock, R. P., & Belley-Côté, E. P. (2018) · JAMA · doi:10.1001/jama.2018.4528 · Cited by 225
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 224
Busse, L. W., Barker, N., & Petersen, C. (2020) · Critical Care · doi:10.1186/s13054-020-2743-8 · Cited by 222
Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance
Mebazaa, A., Tolppanen, H., Mueller, C., Lassus, J., DiSomma, S., Baksyte, G., Cecconi, M., Choi, D. J., Cohen Solal, A., Christ, M., et al. (2016) · Intensive Care Medicine · doi:10.1007/s00134-015-4041-5 · Cited by 220
Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside
Levy, B., Collin, S., Sennoun, N., Ducrocq, N., Kimmoun, A., Asfar, P., Perez, P., & Meziani, F. (2010) · Intensive Care Medicine · doi:10.1007/s00134-010-2045-8 · Cited by 218
“Currently, dopamine and above all norepinephrine are the most used agents without any differences in terms of mortality [53].”
BackgroundAcute Kidney Injury: From Diagnosis to Prevention and Treatment Strategies
Gameiro, J., Fonseca, J. A., Outerelo, C., & Lopes, J. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061704 · Cited by 215
“In vasodilatory states, noradrenaline is the recommended first-line vasopressor [76,97].”
BackgroundDevelopment and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score
Ranzani, O., Singer, M., Salluh, J. I., Shankar‐Hari, M., Pilcher, D., Berger‐Estilita, J., Coopersmith, C. M., Juffermans, N. P., Laffey, J. G., Reinikainen, M., et al. (2025) · JAMA · doi:10.1001/jama.2025.20516 · Cited by 211
Self-citationSurvival After Shock Requiring High-Dose Vasopressor Therapy
Brown, S. M., Lanspa, M. J., Jones, J. P., Kuttler, K. G., Li, Y., Carlson, R., Miller, R. R., Hirshberg, E. L., Grissom, C. K., & Morris, A. H. (2013) · Chest · doi:10.1378/chest.12-1106 · Cited by 209
Zeymer, U., Bueno, H., Granger, C. B., Hochman, J., Huber, K., Lettino, M., Price, S., Schiele, F., Tubaro, M., Vranckx, P., et al. (2020) · European Heart Journal: Acute Cardiovascular Care · doi:10.1177/2048872619894254 · Cited by 208
Vasoactive Drugs in Circulatory Shock
Hollenberg, S. M. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0972ci · Cited by 208
“A more recent multicenter trial randomized 1,679 patients with shock to either dopamine or norepinephrine as first-line therapy, and found no significant difference in the primary end point of 28-day mortality (41).”
BackgroundMethodInfluentialRubí, B., & Maechler, P. (2010) · Endocrinology · doi:10.1210/en.2010-0745 · Cited by 207
Sepsis-Induced Cardiomyopathy: Mechanisms and Treatments
Liu, Y.-C., Yu, M.-M., Shou, S.-T., & Chai, Y.-F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01021 · Cited by 207
“The use of dopamine was associated with a greater number of adverse events (60).”
BackgroundHamzaoui, O., Georger, J.-F., Monnet, X., Ksouri, H., Maizel, J., Richard, C., & Teboul, J.-L. (2010) · Critical Care · doi:10.1186/cc9207 · Cited by 206
“Norepinephrine is considered more potent [1,2] and induces fewer adverse effects than dopamine [ 3 ].”
Background2024 Clinical practice guidelines for Chronic heart failure
Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 204
for the CardShock study investigators, Tarvasmäki, T., Lassus, J., Varpula, M., Sionis, A., Sund, R., Køber, L., Spinar, J., Parissis, J., Banaszewski, M., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1387-1 · Cited by 203
“A randomized study comparing dopamine with noradrenaline in shock showed that arrhythmia was more frequent in the dopamine group, the drug was discontinued more often due to severe arrhythmia, and the outcome was worse in the subgroup with CS [11].”
BackgroundKanji, H. D., McCallum, J., Sirounis, D., MacRedmond, R., Moss, R., & Boyd, J. H. (2014) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.04.008 · Cited by 200
“Inotropic therapy is not without significant adverse effects, as up to 25% of patients experience serious tachyarrythmias [1].”
BackgroundInfluentialShock in acute myocardial infarction: the Cape Horn for trials?
Thiele, H., Allam, B., Chatellier, G., Schuler, G., & Lafont, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq220 · Cited by 198
Pharmacotherapy Update on the Use of Vasopressors and Inotropes in the Intensive Care Unit
Jentzer, J. C., Coons, J. C., Link, C. B., & Schmidhofer, M. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414559838 · Cited by 197
“Norepinephrine carries a lower tachyarrhythmia risk than either dopamine or epinephrine when used for vasopressor support (Table 2).(5,6,8,70,71) Phenylephrine and vasopressin reduce HR and do not cause tachyarrhythmias but may provoke myocardial ischemia via coronary vasoconstriction.”
BackgroundMethodInfluentialUse of inotropes and vasopressor agents in critically ill patients
Bangash, M. N., Kong, M., & Pearse, R. M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01588.x · Cited by 197
“It is likely that these findings, in fact, relate to harmful chronotropic effects of dopamine resulting in tachycardia and perhaps myocardial ischaemia (De Backer et al., 2010).”
BackgroundResultInfluentialOptimal perioperative management of arterial blood pressure
Lonjaret, L., Lairez, O., Geeraerts, T., & Minville, V. (2014) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s45292 · Cited by 197
Management of cardiogenic shock complicating myocardial infarction
Mebazaa, A., Combes, A., van Diepen, S., Hollinger, A., Katz, J. N., Landoni, G., Hajjar, L. A., Lassus, J., Lebreton, G., Montalescot, G., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5214-9 · Cited by 195
“The following agents are generally not considered firstline therapies in CS: (1) Dopamine was shown to be associated with increased 28-day mortality as compared to norepinephrine, although this effect may be explained by chance [44].”
BackgroundMethodInfluentialPostoperative Critical Care of the Adult Cardiac Surgical Patient. Part I
Stephens, R. S., & Whitman, G. J. R. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000001059 · Cited by 197
Current use of vasopressors in septic shock
Scheeren, T. W. L., Bakker, J., De Backer, D., Annane, D., Asfar, P., Boerma, E. C., Cecconi, M., Dubin, A., Dünser, M. W., Duranteau, J., et al. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0498-7 · Cited by 192
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Vasoplegia After Cardiovascular Procedures—Pathophysiology and Targeted Therapy
Shaefi, S., Mittel, A., Klick, J., Evans, A., Ivascu, N. S., Gutsche, J., & Augoustides, J. G. T. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.10.032 · Cited by 187
We should abandon randomized controlled trials in the intensive care unit
Vincent, J.-L. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181f208ac · Cited by 185
“Some may argue this is true for all trials, but this is not the case: For example, in the recent study by De Backer et al (29) comparing dopamine with norepinephrine as first-line vasopressor in patients with shock, there were limited exclusion criteria and, of 2011 patients assessed for eligibility, 1679 (84”
ResultSelf-citationLüsebrink, E., Binzenhöfer, L., Adamo, M., Lorusso, R., Mebazaa, A., Morrow, D. A., Price, S., Jentzer, J. C., Brodie, D., Combes, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01818-x · Cited by 184
Acute Complications of Myocardial Infarction in the Current Era: Diagnosis and Management
Bajaj, A., Sethi, A., Rathor, P., Suppogu, N., & Sethi, A. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000232 · Cited by 180
“When response to dobutamine is inadequate or the patient's presenting systolic blood pressure is less than 70 mm Hg, the use of vasopressors, preferably norepinephrine, is suggested on the basis of the recent data.(28) Cardiogenic shock carries significant mortality with 30-day mortality of approximately 40% and 1 yea…”
BackgroundSeptic Shock: Advances in Diagnosis and Treatment
Seymour, C. W., & Rosengart, M. R. (2015) · JAMA · doi:10.1001/jama.2015.7885 · Cited by 149
A plea for personalization of the hemodynamic management of septic shock
De Backer, D., Cecconi, M., Chew, M. S., Hajjar, L., Monnet, X., Ospina-Tascón, G. A., Ostermann, M., Pinsky, M. R., & Vincent, J.-L. (2022) · Critical Care · doi:10.1186/s13054-022-04255-y · Cited by 177
Self-citationRecommendations for sepsis management in resource-limited settings
Dünser, M. W., Festic, E., Dondorp, A., Kissoon, N., Ganbat, T., Kwizera, A., Haniffa, R., Baker, T., Schultz, M. J., & Global Intensive Care Working Group of the European Society of Intensive Care Medicine (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2468-5 · Cited by 176
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 178
Myocardial Dysfunction and Shock after Cardiac Arrest
Jentzer, J. C., Chonde, M. D., & Dezfulian, C. (2015) · BioMed Research International · doi:10.1155/2015/314796 · Cited by 174
Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis
Stolk, R. F., van der Poll, T., Angus, D. C., van der Hoeven, J. G., Pickkers, P., & Kox, M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0862cp · Cited by 148
“significantly decreased mortality was only found in a subgroup of cardiogenic shock patients (44).”
InfluentialFrancis, G. S., Bartos, J. A., & Adatya, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.016 · Cited by 172
“A comparator study published in 2010 indicated that a subset of patients with cardiogenic shock derived more survival benefit from norepinephrine than from dopamine (48).”
BackgroundInfluentialExperts’ recommendations for the management of adult patients with cardiogenic shock
Levy, B., Bastien, O., Bendjelid, K., Cariou, A., Chouihed, T., Combes, A., Mebazaa, A., Megarbane, B., Plaisance, P., Ouattara, A., et al. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0052-1 · Cited by 172
“reported a reduction in mortality with norepinephrine when compared with dopamine [12].”
Pathophysiology of Septic Shock
Russell, J. A., Rush, B. N. M., & Boyd, J. H. (2017) · Critical Care Clinics · doi:10.1016/j.ccc.2017.08.005 · Cited by 172
Vincent, J.-L., Nielsen, N. D., Shapiro, N. I., Gerbasi, M. E., Grossman, A., Doroff, R., Zeng, F., Young, P. J., & Russell, J. A. (2018) · Annals of Intensive Care · doi:10.1186/s13613-018-0448-9 · Cited by 170
Self-citationAn updated “norepinephrine equivalent” score in intensive care as a marker of shock severity
Kotani, Y., Di Gioia, A., Landoni, G., Belletti, A., & Khanna, A. K. (2023) · Critical Care · doi:10.1186/s13054-023-04322-y · Cited by 169
“[33] 2010 New England Journal of Medicine The dose of dopamine was consistently 100 times as much as that of norepinephrine during seven days after randomization”
Pais, T., Jorge, S. C., & Lopes, J. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115924 · Cited by 170
Outcome of patients with septic shock and high-dose vasopressor therapy
Auchet, T., Regnier, M.-A., Girerd, N., & Levy, B. (2017) · Annals of Intensive Care · doi:10.1186/s13613-017-0261-x · Cited by 166
Nolan, J. P., Sandroni, C., Cariou, A., Cronberg, T., D’Arrigo, S., Haywood, K. L., Hoedemaekers, A. C. W. E., Lilja, G., Nikolaou, N. I., Olasveengen, T. M., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08117-3 · Cited by 168
Sepsis-induced myocardial dysfunction
Walley, K. R. (2018) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000507 · Cited by 165
Knaup, H., Stahl, K., Schmidt, B. M. W., Idowu, T. O., Busch, M., Wiesner, O., Welte, T., Haller, H., Kielstein, J. T., Hoeper, M. M., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2220-9 · Cited by 165
Severe Sepsis and Septic Shock in Pregnancy
Barton, J. R., & Sibai, B. M. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318263a52d · Cited by 164
Görenek, B., Lundqvist, C. B., Brugada, J., Camm, A. J., Hindricks, G., Huber, K., Kirchhof, P. F., Kück, K., Kudaiberdieva, G., Lin, T., et al. (2014) · EP Europace · doi:10.1093/europace/euu208 · Cited by 165
Maas, J. J., Pinsky, M. R., de Wilde, R. B., de Jonge, E., & Jansen, J. R. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e318265ea64 · Cited by 163
“org 143 Norepinephrine (NE) is the vasopressor of choice in septic shock (1) because of its ability to maintain vasomotor tone, but it is also recommended as treatment for resistant cardiogenic shock (2, 3).”
BackgroundNagendran, M., Russell, J. A., Walley, K. R., Brett, S. J., Perkins, G. D., Hajjar, L., Mason, A. J., Ashby, D., & Gordon, A. C. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05620-2 · Cited by 161
Timing of vasopressor initiation and mortality in septic shock: a cohort study
Beck, V., Chateau, D., Bryson, G. L., Pisipati, A., Zanotti, S., Parrillo, J. E., Kumar, A., & The Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (2014) · Critical Care · doi:10.1186/cc13868 · Cited by 161
“While there has been much study into the comparison of vasopressors/inotropes individually and in combination [33-35], there has been a relative paucity in the literature regarding the timing of their initiation in septic shock.”
BackgroundSaadeh, Y. S., Smith, B. W., Joseph, J. R., Jaffer, S. Y., Buckingham, M. J., Oppenlander, M. E., Szerlip, N. J., & Park, P. (2017) · Neurosurgical FOCUS · doi:10.3171/2017.8.focus17428 · Cited by 161
Management of refractory cardiogenic shock
Reyentovich, A., Barghash, M. H., & Hochman, J. S. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.96 · Cited by 160
A global perspective on vasoactive agents in shock
Annane, D., Ouanes-Besbes, L., Backer, D. D., Du, B., Gordon, A. C., Glenn Hernández, P., Olsen, K. M., Osborn, T. M., Peake, S., Russell, J. A., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5242-5 · Cited by 160
Thiele, H., Schuler, G., Neumann, F.-J., Hausleiter, J., Olbrich, H.-G., Schwarz, B., Hennersdorf, M., Empen, K., Fuernau, G., Desch, S., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.03.012 · Cited by 159
Recommendations for the Management of Crush Victims in Mass Disasters
Sever, M. S., Vanholder, R., the RDRTF of ISN Work Group on Recommendations for the Management of Crush Victims in Mass Disasters, Ashkenazi, I., Becker, G., Better, O., Covic, A., De Smet, M., Eckardt, K.-U., Eknoyan, G., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs156 · Cited by 158
“Therefore, in considering prevention, try to expand intravascular volume by using crystalloids (rather than colloids) as initial management and also treat hypotension by vasopressors in patients with vasomotor shock [109, 210–212].”
BackgroundUpdate of Sepsis in the Intensive Care Unit
Genga, K. R., & Russell, J. A. (2017) · Journal of Innate Immunity · doi:10.1159/000477419 · Cited by 158
Tagami, T., Matsui, H., Horiguchi, H., Fushimi, K., & Yasunaga, H. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12643 · Cited by 158
Boerma, E. C., & İnce, C. (2010) · Intensive Care Medicine · doi:10.1007/s00134-010-1970-x · Cited by 156
Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time
Jentzer, J. C., Ahmed, A., Vallabhajosyula, S., Burstein, B. J., Tabi, M., Barsness, G. W., Murphy, J. G., Best, P. J. M., & Bell, M. R. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.054 · Cited by 155
Nolan, J. P., Sandroni, C., Cariou, A., Cronberg, T., D’Arrigo, S., Haywood, K. L., Hoedemaekers, A. C. W. E., Lilja, G., Nikolaou, N. I., Olasveengen, T. M., et al. (2025) · Resuscitation · doi:10.1016/j.resuscitation.2025.110809 · Cited by 158
Personalizing blood pressure management in septic shock
Kato, R., & Pinsky, M. R. (2015) · Annals of Intensive Care · doi:10.1186/s13613-015-0085-5 · Cited by 152
“It had been suggested that dopamine might increase splanchnic blood flow in well-resuscitated patients with septic shock [33], but SOAP II study failed to show this [29].”
BackgroundManagement of critically-ill cirrhotic patients
Ginès, P., Fernández, J., Durand, F., & Saliba, F. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60003-8 · Cited by 152
Postoperative complications of patients undergoing cardiac surgery
Ball, L., Costantino, F., & Pelosi, P. P. (2016) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000319 · Cited by 152
Cardiogenic Shock Due to Myocardial Infarction
Werdan, K., Ruß, M., Buerke, M., Delle‐Karth, G., Geppert, A., & Schöndube, F. A. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0343 · Cited by 149
Fluid management in the critically ill
Vincent, J. (2019) · Kidney International · doi:10.1016/j.kint.2018.11.047 · Cited by 148
Self-citationS3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00685-0 · Cited by 148
Inoue, T., Manley, G. T., Patel, N., & Whetstone, W. D. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2013.3061 · Cited by 148
Creager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.005 · Cited by 145
Vasopressors in septic shock: which, when, and how much?
Shi, R., Hamzaoui, O., Vita, N. D., Monnet, X., & Teboul, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.04.24 · Cited by 143
“A large RCT confirmed that dopamine compared with NE was associated with more frequent adverse events (especially tachyarrhythmias) even though no significant difference in mortality was observed (25).”
Early interventions in severe sepsis and septic shock: a review of the evidence one decade later.
Rivers, E., Katranji, M. F., Jaehne, K. A., Brown, S., Dagher, G. A., Cannon, C. M., & Coba, V. E. (2012) · PubMed · Cited by 142
Part 10: Paediatric basic and advanced life support
de Caen, A. R., Kleinman, M. E., Chameides, L., Atkins, D. L., Berg, R. A., Berg, M., Bhanji, F., Biarent, D., Bingham, R. M., Coovadia, A. H., et al. (2010) · Resuscitation · doi:10.1016/j.resuscitation.2010.08.028 · Cited by 140
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 167
Challenges with Diagnosing and Managing Sepsis in Older Adults
Clifford, K. M., Dy‐Boarman, E. A., Haase, K. K., Maxvill, K., Pass, S. E., & Álvarez, C. (2016) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1135052 · Cited by 140
Recommandations sur la réanimation du choc hémorragique
Duranteau, J., Asehnoune, K., Pierre, S., Ozier, Y. M., Léone, M., & Lefrant, J. (2015) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2014.12.007 · Cited by 138
Association Between Presence of a Cardiac Intensivist and Mortality in an Adult Cardiac Care Unit
Na, S. J., Chung, C. R., Jeon, K., Park, C.-M., Suh, G. Y., Ahn, J., Carriere, K. C., Song, Y. B., Choi, J., Hahn, J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.947 · Cited by 136
“showed significantly higher mortality rates in patients treated with dopamine than in those treated with norepinephrine among patients with cardiogenic shock (21).”
BackgroundDopaminergic Regulation of Innate Immunity: a Review
Pinoli, M., Marino, F., & Cosentino, M. (2017) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9749-2 · Cited by 137
JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis
Nagai, T., Inomata, T., Kohno, T., Sato, T., Tada, A., Kubo, T., Nakamura, K., Oyama‐Manabe, N., Ikeda, Y., Fujino, T., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-22-0696 · Cited by 137
Optimum Blood Pressure in Patients With Shock After Acute Myocardial Infarction and Cardiac Arrest
Ameloot, K., Jakkula, P., Hästbacka, J., Reinikainen, M., Pettilä, V., Loisa, P., Tiainen, M., Bendel, S., Birkelund, T., Belmans, A., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.043 · Cited by 135
Gorenek, B., Lundqvist, C. B., Terradellas, J. B., Camm, A. J., Hindricks, G., Huber, K., Kirchhof, P., Kuck, K.-H., Kudaiberdieva, G., Lin, T., et al. (2015) · European Heart Journal: Acute Cardiovascular Care · doi:10.1177/2048872614550583 · Cited by 128
Shock – Classification and Pathophysiological Principles of Therapeutics
Kislitsina, O. N., Rich, J. D., Wilcox, J. E., Pham, D. T., Churyla, A., Vorovich, E. B., Ghafourian, K., & Yancy, C. W. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x15666181212125024 · Cited by 134
Wang, S., Cao, C., Chen, Z., Bankaitis, V., Tzima, E., Sheibani, N., & Burridge, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045499 · Cited by 120
“NE is an agonist [41] of a-adrenergic receptors in pericytes and smooth muscle cells, whereas Tolazoline is an antagonist [42].”
BackgroundRamaswamy, K. N., Singhi, S. C., Jayashree, M., Bansal, A., & Nallasamy, K. (2016) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000954 · Cited by 133
“In adults with septic shock, there is strong evidence that dopamine is associated with increased mortality and adverse events (7, 8).”
BackgroundEarly recognition and management of sepsis in adults: the first six hours.
Gauer, R. L. (2013) · PubMed · Cited by 136
Management of cardiogenic shock
Thiele, H., de Waha‐Thiele, S., Freund, A., Zeymer, U., Desch, S., & Fitzgerald, S. (2021) · EuroIntervention · doi:10.4244/eij-d-20-01296 · Cited by 132
Sepse: atualidades e perspectivas
Siqueira‐Batista, R., Gomes, A. P., Calixto‐Lima, L., Vitorino, R. R., Perez, M. C. A., de Mendonça, E. G., Oliveira, M. G. D. A., & Geller, M. (2011) · Revista Brasileira de Terapia Intensiva · doi:10.1590/s0103-507x2011000200014 · Cited by 134
Intensive Care Unit–Acquired Weakness: Implications for Physical Therapist Management
Nordon‐Craft, A., Moss, M., Quan, D., & Schenkman, M. L. (2012) · Physical Therapy · doi:10.2522/ptj.20110117 · Cited by 131
Use of Inotropic Agents in Treatment of Systolic Heart Failure
Tariq, S., & Aronow, W. S. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226147 · Cited by 129
“Norepinephrine use in patients with shock has been compared to dopamine [3].”
BackgroundInfluentialGordon, A. C., Mason, A. J., Perkins, G. D., Stotz, M., Terblanche, M., Ashby, D., & Brett, S. J. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000212 · Cited by 119
Surviving Sepsis Campaign: Research Priorities for Sepsis and Septic Shock
Coopersmith, C. M., Backer, D. D., Deutschman, C. S., Ferrer, R., Lat, I., Machado, F. R., Martin, G. S., Martín‐Loeches, I., Nunnally, M., Antonelli, M. M., et al. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003225 · Cited by 129
Advances in the Management of Sepsis and the Understanding of Key Immunologic Defects
Skrupky, L. P., Kerby, P. W., & Hotchkiss, R. S. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31823422e8 · Cited by 128
The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Rudiger, A., & Singer, M. (2013) · Current Vascular Pharmacology · doi:10.2174/1570161111311020008 · Cited by 126
Management of cardiogenic shock: a narrative review
Laghlam, D., Benghanem, S., Ortuno, S., Bouabdallaoui, N., Manzo‐Silberman, S., Hamzaoui, O., & Aïssaoui, N. (2024) · Annals of Intensive Care · doi:10.1186/s13613-024-01260-y · Cited by 126
“Compared to norepinephrine, dopamine was associated with a higher rate of arrhythmias in the CS subgroup (280 patients) and in the overall population (1679 patients) and was associated with a higher risk of mortality in the CS subgroup [94].”
ResultClinical review: Circulatory shock - an update: a tribute to Professor Max Harry Weil
Vincent, J., İnce, C., & Bakker, J. (2012) · Critical Care · doi:10.1186/cc11510 · Cited by 126
“Norepinephrine is preferred over dopamine, as it is associated with lower mortality rates in cardiogenic [38] and in septic [39] shock.”
Self-citationYarnell, C. J., Abrams, D. C., Baldwin, M. R., Brodie, D., Fan, E., Ferguson, N. D., Hua, M. S., Madahar, P., McAuley, D. F., Munshi, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30471-9 · Cited by 123
Hasegawa, D., Sato, R., Prasitlumkum, N., Nishida, K., Takahashi, K., Yatabe, T., & Nishida, O. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.01.009 · Cited by 123
Physiological changes after fluid bolus therapy in sepsis: a systematic review of contemporary data
Glassford, N. J., Eastwood, G. M., & Bellomo, R. (2014) · Critical Care · doi:10.1186/s13054-014-0696-5 · Cited by 111
Therapeutic Strategies for High-Dose Vasopressor-Dependent Shock
Bassi, E., Park, M., & Azevedo, L. C. P. (2013) · Critical Care Research and Practice · doi:10.1155/2013/654708 · Cited by 123
“Hindawi Publishing Corporation Critical Care Research and Practice Volume 2013, Article ID 654708, 10 pages http://dx.doi.org/10.1155/2013/654708”
BackgroundInfluentialNorepinephrine or Dopamine for Septic Shock: Systematic Review of Randomized Clinical Trials
Vasu, T. S., Cavallazzi, R., Hirani, A., Kaplan, G., Leiby, B., & Marik, P. E. (2012) · Journal of Intensive Care Medicine · doi:10.1177/0885066610396312 · Cited by 108
Medlej, K., Kazzi, A. A. N., Chehadeh, A. A.-H., Eldine, M. S., Chami, A., Bachir, R. H., Zebian, D., & Dagher, G. A. (2017) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2017.09.007 · Cited by 121
Chakroborty, D., Sarkar, C., Yu, H., Wang, J., Liu, Z., Dasgupta, P. S., & Basu, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108696108 · Cited by 119
Metadata
- Authors
- De Backer, D., Biston, P., Devriendt, J., Madl, C., Chochrad, D., Aldecoa, C., Brasseur, A., Defrance, P., Gottignies, P., & Vincent, J.-L.
- Affiliations
- Université Libre de Bruxelles (BE)
- Medical University of Vienna (AT)
- Centre hospitalier Etterbeek-Ixelles (BE)
- Erasmus Hospital (BE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-03-04
- Volume
- 362
- Issue
- 9
- Pages
- 779-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095944485
- Cited by
- 1,940
- References
- 31
- Citations by year
- 2026: 98 · 2025: 107 · 2024: 140 · 2023: 115 · 2022: 125 · 2021: 132 · 2020: 135 · 2019: 138 · 2018: 106 · 2017: 139 · 2016: 99 · 2015: 122 · 2014: 120 · 2013: 96 · 2012: 110
- FWCI
- 83.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Hemodynamic Monitoring and Therapy
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Trauma, Hemostasis, Coagulopathy, Resuscitation
- Keywords
- dopamine, norepinephrine, vasopressors, shock, cardiogenic shock, septic shock, hypovolemic shock, 28-day mortality, cardiac arrhythmias, epinephrine, vasopressin, organ support, adverse events, subgroup analysis, vasopressor weaning
- MeSH terms
- Aged, Arrhythmias, Cardiac, Combined Modality Therapy, Dopamine, Female, Fluid Therapy, Humans, Male, Middle Aged, Norepinephrine, Shock, Vasoconstrictor Agents, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.